PATENT CLAIM ANALYSIS

Application Number: 16309400
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "078290"]

Abstract:
An anti-tumor cocktail comprises a combination of a commercial anti-tumor drug (1), such as 9-acridinecarboxylic acid, in association with an antioxidant (2), such as Coenzyme Q10, and a P-glycoprotein inhibitor (3), such as metformin, ketoconazole, quinidine, verapamil, cyclosporin, erythromycin, spironolactone, itraconazole, tariquidar, zosuquidar, elacridar, laniquidar, ontogen, imidazole, anthranilamide, dexverapamil and/or dexniguldipine. The anti-tumor cocktail selectively destroys solid tumor cells without affecting rapidly replicating healthy cells.

Claim (Index 2):
The Anti-tumor Cocktail, according to  claim 1 , wherein in the presence of tumor acidity, the anti-tumor agent having a negative charge will be absorbed by the tumor cells only, which have an excess of positive charge due to their acidity, saving healthy cells which have a neutral charge.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 98.0
- Lexical Diversity: 1.57627
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11706868', '13198850', '10568765', '14106987', '09789496']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7249181120115008
- 35 USC 102 Novelty (BERT): 0.5005178737911226
- Combined Prediction Score: 0.702478088189463
- Mean Citation Score: 150.01206399999995
- Max Citation Score: 166.91772
- Similarity Product: 97.28394039153814

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test